
AstraZeneca has jettisoned another non-essential asset with the sale of Synagis (palivizumab), a preventative treatment for infections relating to respiratory …
AstraZeneca’s MedImmune subsidiary is to receive $92.5 million as part of a legal settlement involving its respiratory drug Synagis. PDL …

